

On page 5, the following heading is under the third paragraph, following the line "anti-CD19":

D7

DETAILED DESCRIPTION OF THE INVENTION

In the Claims

MPF 2 404, 01

1. (Twice Amended) A recombinant antibody product, comprising the V_H domain of the antibody produced by the hybridoma of ATCC deposit number CRL 8001, wherein the cysteine at position H100A of said V_H domain is substituted with a polar amino acid, wherein said position H100A is according to the Kabat numbering system, wherein said recombinant antibody product comprises the amino acid sequence depicted by SEQ ID NO:2.

2. (Twice Amended) The recombinant antibody product according to claim 1, characterized in that the polar amino acid is serine.

Claim 3 is cancelled.

4. (Twice Amended) A method for the production of the recombinant antibody product according to claim 1 or 2, characterized by the steps of:

- obtaining mRNA from freshly subcloned hybridoma cells of ATCC deposit number CRL 8001 and transcription into cDNA,
- amplifying the DNA coding for the variable domains of the light and heavy chains by means of PCR,
- cloning of the DNA obtained in b) into a vector adapted for site-specific mutagenesis as well as introduction of a mutation in said position H100A of the V_H domain, wherein said position H100A is according to the Kabat numbering system, wherein said mutation is the substitution of a cysteine with a polar amino acid, and
- inserting the mutated DNA obtained in c) in an expression vector and expression in a suitable expression system.

D10
5. (Amended) The method according to claim 4, wherein the amplifying of step b) uses primers having the nucleotide sequences depicted by SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11.

D11
6. (Amended) The method according to claim 4, wherein the vector used in step c) is pCR-Skript SK(+).

7. (Amended) The method according to claim 4, wherein said cloning uses a primer comprising the sequence depicted by SEQ ID NO: 7.

✓
Claim 8 is cancelled.

D12
9. (Amended) The method according to claim 4, wherein the expression takes place in XLI-Blue *E. coli* cells.

12. (Reiterated) The method according to claim 5, wherein the vector used in step c) is pCR-Skript SK(+).

N.E. Duplants
13. (Reiterated) The method according to claim 5, wherein said cloning uses a primer comprising the sequence depicted by SEQ ID NO: 7.

14. (Reiterated) The method according to claim 6, wherein said cloning uses a primer comprising the sequence depicted by SEQ ID NO: 7.

✓ ✓ ✓
Claims 15-17 are cancelled.

18. (Reiterated) The method according to claim 4, wherein the expression takes place in XLI-Blue *E. coli* cells.

N.E. Duplants
19. (Reiterated) The method according to claim 5, wherein the expression takes place

in XLI-Blue *E. coli* cells.

W.E.
Appl. w/7
20. (Reiterated) The method according to claim 6, wherein the expression takes place in XLI-Blue *E. coli* cells.

21. (Reiterated) The method according to claim 7, wherein the expression takes place in XLI-Blue *E. coli* cells.

✓
Claim 22 is cancelled.

23. (Reiterated) A peptide comprising the amino acid sequence depicted by SEQ ID NO:2.

W.E.
Appl. w/7
24. (Reiterated) An antibody comprising the peptide according to Claim 23.

25. (Reiterated) A single-chain antibody comprising the peptide according to Claim 23.

26. (Reiterated) A bispecific antibody comprising the peptide according to Claim 23.

27. (Reiterated) A recombinant antibody product comprising the peptide according to Claim 23.

THE REMARKS

The Amendments

The specification is amended to add Section headings in order to bring the specification in accordance with 37 CFR §1.1.77(c).

The specification is amended to add the sequences and SEQ ID NOs. of the primers Bi5, Bi8, Bi4 and Bi3f. The sequences of Bi5, Bi8 and Bi4 are incorporated from Dübel, et al. (*J. Immunol. Meth.* 175:89-95, 1994; page 91, Table 1). The sequence of Bi3f is incorporated